{"title":"一名携带 KIT 外显子 11 突变的胸腺癌患者对伦伐替尼的快速反应和停药后的疾病复发：病例报告","authors":"Masahiro Torasawa MD , Tatsuya Yoshida MD, PhD , Kouya Shiraishi PhD , Naoko Goto BS , Toshihide Ueno PhD , Hitoshi Ichikawa MD, PhD , Shigehiro Yagishita MD, PhD , Shinji Kohsaka MD, PhD , Yasushi Goto MD, PhD , Yasushi Yatabe MD, PhD , Akinobu Hamada PhD , Hiroyuki Mano MD, PhD , Yuichiro Ohe MD, PhD","doi":"10.1016/j.jtocrr.2024.100657","DOIUrl":null,"url":null,"abstract":"<div><p>Lenvatinib, a multitarget tyrosine kinase inhibitor for c-Kit and other kinases, has exhibited promising efficacy in treating advanced or metastatic thymic carcinoma (TC). Here, we present the case of a patient with metastatic TC harboring a <em>KIT</em> exon 11 deletion and amplification. The patient exhibited a remarkable response to lenvatinib but experienced rapid disease progression after discontinuation of lenvatinib, referred to as a “disease flare.” This case report indicates that <em>KIT</em> mutations and amplification can predict lenvatinib response in patients with TC. However, in such cases, there might be a risk of disease flares after lenvatinib discontinuation.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 4","pages":"Article 100657"},"PeriodicalIF":3.0000,"publicationDate":"2024-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666364324000274/pdfft?md5=b9ec22f6643d5497789d13c673ed5b47&pid=1-s2.0-S2666364324000274-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Rapid Response to Lenvatinib and Disease Flare After Discontinuation in a Patient With Thymic Carcinoma Harboring KIT Exon 11 Mutation: A Case Report\",\"authors\":\"Masahiro Torasawa MD , Tatsuya Yoshida MD, PhD , Kouya Shiraishi PhD , Naoko Goto BS , Toshihide Ueno PhD , Hitoshi Ichikawa MD, PhD , Shigehiro Yagishita MD, PhD , Shinji Kohsaka MD, PhD , Yasushi Goto MD, PhD , Yasushi Yatabe MD, PhD , Akinobu Hamada PhD , Hiroyuki Mano MD, PhD , Yuichiro Ohe MD, PhD\",\"doi\":\"10.1016/j.jtocrr.2024.100657\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Lenvatinib, a multitarget tyrosine kinase inhibitor for c-Kit and other kinases, has exhibited promising efficacy in treating advanced or metastatic thymic carcinoma (TC). Here, we present the case of a patient with metastatic TC harboring a <em>KIT</em> exon 11 deletion and amplification. The patient exhibited a remarkable response to lenvatinib but experienced rapid disease progression after discontinuation of lenvatinib, referred to as a “disease flare.” This case report indicates that <em>KIT</em> mutations and amplification can predict lenvatinib response in patients with TC. However, in such cases, there might be a risk of disease flares after lenvatinib discontinuation.</p></div>\",\"PeriodicalId\":17675,\"journal\":{\"name\":\"JTO Clinical and Research Reports\",\"volume\":\"5 4\",\"pages\":\"Article 100657\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-02-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2666364324000274/pdfft?md5=b9ec22f6643d5497789d13c673ed5b47&pid=1-s2.0-S2666364324000274-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JTO Clinical and Research Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666364324000274\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JTO Clinical and Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666364324000274","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Rapid Response to Lenvatinib and Disease Flare After Discontinuation in a Patient With Thymic Carcinoma Harboring KIT Exon 11 Mutation: A Case Report
Lenvatinib, a multitarget tyrosine kinase inhibitor for c-Kit and other kinases, has exhibited promising efficacy in treating advanced or metastatic thymic carcinoma (TC). Here, we present the case of a patient with metastatic TC harboring a KIT exon 11 deletion and amplification. The patient exhibited a remarkable response to lenvatinib but experienced rapid disease progression after discontinuation of lenvatinib, referred to as a “disease flare.” This case report indicates that KIT mutations and amplification can predict lenvatinib response in patients with TC. However, in such cases, there might be a risk of disease flares after lenvatinib discontinuation.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
